Switch Trial from Several Times to Once Daily Oral Mesalazine Administration in Patients with Quiescent Ulcerative Colitis

Switch Trial from Several Times to Once Daily Oral Mesalazine Administration in Patients with Quiescent Ulcerative Colitis - Once Daily Oral Mesalazine Swich Trial in UC-Patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008352

Enrollment

Registered

2012-08-01

Start date

2012-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative Colitis

Interventions

Switch from several times to once daily oral mesalazine administration

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who keeps remission state more than 8 weeks by several times oral mesarazine administration CAI score is 4 and less Patients who have informed consent

Exclusion criteria

Exclusion criteria: Patients refractory to oral mesalazine Patients treated by infliximab within 12 weeks Patients treated by azathiopurine and 6MP within 12 weeks Patients treated by tacrolimus within 12 weeks Patients treated by leukocyteapheresis within 12 weeks Patients in maternity and lactation Patients treated by surgery within 6 months

Design outcomes

Primary

Measure	Time frame
Changes of clinical activity index (CAI)in week 48	—

Secondary

Measure	Time frame
Changes of adherece in week 48 Changes of stool calprotectin concentration in week 48 Remission rates in week 48 Changes of CRP titer in week 48 Changes of stool number and bloody stoolin week 48 Safety	—

Countries

Japan

Contacts

Public ContactShingo Kato

Saitama Medical Center, Saitama Medical University Department of Gastroenterology and Hepatology

skato@saitama-med.ac.jp049-228-3564

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026